← FDA DRUG APPROVALS

FDA ANDA · ANDA217451

OSELTAMIVIR PHOSPHATE

Sponsor: CEDIPROF INC

APPLICATION
ANDA217451
TYPE
ANDA
ORIGINAL APPROVAL
2024-12-03
LATEST ACTION
2024-12-03
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

OSELTAMIVIR PHOSPHATEDiscontinued
OSELTAMIVIR PHOSPHATE EQ 45MG BASE · CAPSULE · ORAL
OSELTAMIVIR PHOSPHATEDiscontinued
OSELTAMIVIR PHOSPHATE EQ 75MG BASE · CAPSULE · ORAL
OSELTAMIVIR PHOSPHATEDiscontinued
OSELTAMIVIR PHOSPHATE EQ 30MG BASE · CAPSULE · ORAL

Approval history

2024-12-03UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →